Journal
DIABETIC MEDICINE
Volume 28, Issue 7, Pages 815-817Publisher
WILEY
DOI: 10.1111/j.1464-5491.2011.03255.x
Keywords
antibody seroconversion; influenza A (H1N1) 2009 monovalent vaccine; Type 2 diabetes mellitus
Categories
Funding
- Ministry of Education, Science and Technology [2010-0001664]
Ask authors/readers for more resources
Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA. Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range orwith longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available